Respiratory virus season has arrived, and hopefully you’re up to date on vaccinations that can help prevent infectious diseases including COVID, the flu, whooping cough, and respiratory syncytial ...

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes causing invasive disease. [134] In the face of these changes ...

Anticipated growth for ‘Saudi Arabia 23 Valent Pneumococcal Polysaccharide Vaccine Market’ is significant from 2024 to 2032. The market showed steady growth in 2024 and is expected to continue rising ...

The following is a summary of “A nationwide study of two decades of invasive pneumococcal disease in the Faroe Islands, ...

The pneumococcal polysaccharide vaccine (PPV) is currently recommended for older adults and high-risk subjects, including patients with chronic obstructive pulmonary disease (COPD) and asthma.

Throughout history, immunisation has helped protect millions of children against infectious and life-threatening diseases. Immunisation helps to strengthen your child’s immune system to fight diseases ...

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

The Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays.

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

“During harmattan, the risk of various health issues, including respiratory problems and dehydration, increases, and we need to take preventive measures. “We need to keep the body hydrated by drinking ...

PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...